Murtuza Kothawala
Neurology with Special Qualifications in Child Neurology · Orlando, FLNPI 1477585123
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,491 of the $5,435 with a category attached, or 82.6%. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,549 and has fallen 97.0% since, to $77 in 2025.
Across 221 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$935
- Supernus Pharmaceuticals, Inc.$867
- Sunovion Pharmaceuticals Inc.$600
- Eisai Inc.$290
- Tris Pharma Inc$282
- UCB, Inc.$280
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$5009%
- Travel & lodging$3046%
- Food & beverage$4,49183%
- Education$1403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 15 | $935 |
| Supernus Pharmaceuticals, Inc. | 20 | $867 |
| Sunovion Pharmaceuticals Inc. | 34 | $600 |
| Eisai Inc. | 16 | $290 |
| Tris Pharma Inc | 14 | $282 |
| UCB, Inc. | 12 | $280 |
| SK Life Science, Inc. | 9 | $279 |
| Aquestive Therapeutics, Inc. | 13 | $268 |
| Neurelis, Inc. | 12 | $188 |
| Ironshore Pharmaceuticals Inc. | 9 | $180 |
| Greenwich Biosciences, Inc. | 8 | $168 |
| Teva Pharmaceuticals USA, Inc. | 8 | $138 |
| AbbVie(2 entities) | 7 | $132 |
| Biocodex, Inc. | 2 | $107 |
| Adlon Therapeutics L.p. | 6 | $90 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Novartis | 5 | $85 |
| Acadia Pharmaceuticals Inc | 3 | $70 |
| Biomarin Pharmaceutical Inc. | 4 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| Genentech USA, Inc. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Upsher-smith Laboratories LLC | 2 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Corium, LLC | 1 | $29 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| Neos Therapeutics, LP | 2 | $25 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| PTC Therapeutics, Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Rhodes Pharmaceuticals L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$688
- OXTELLAR XR$625
How this compares
$5,435 in reported general payments places this provider in the 60th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bethanechol Chloride | 12 | $851 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Orlando
- Omer Abdul HamidOrlando$283K
- Ngoc Minh leOrlando$19K
- Vikram PrakashOrlando$15K
- Ki-Hyeong LeeOrlando$15K
- Sheila Ramos MartinezOrlando$8K
- Anthony GiordanoOrlando$7K
- Carl BarrOrlando$5K
- Dina DahanOrlando$5K
- Antonio Vazquez-DiazOrlando$5K
- Paul WinnerWest Palm Beach$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.